What is Viridian Therapeutics, Inc.'s gross unrealized gains?

Viridian Therapeutics, Inc. (VRDN) reported gross unrealized gains of $52K in Q1 2026.

How has Viridian Therapeutics, Inc.'s gross unrealized gains changed year-over-year?

Viridian Therapeutics, Inc.'s gross unrealized gains decreased by 90.1% year-over-year, from $523K to $52K.

What is the long-term trend for Viridian Therapeutics, Inc.'s gross unrealized gains?

Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s gross unrealized gains has grown at a 201.4% compound annual growth rate (CAGR), from $6K to $495K.

Viridian Therapeutics, Inc. VRDN Gross Unrealized Gains

Gross Unrealized Gains at other companies

AmgenAMGN

——

Vir Biotechnology, Inc.VIR

——

Nektar TherapeuticsNKTR

——

Krystal Biotech, Inc.KRYS

——

BridgeBio PharmaBBIO

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

See full

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

See full

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

See full

Market cap$1.91B+82.0%

Enterprise value$1.77B+85.0%

P/S26.9×-3,445×

Profitability

See full

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

See full

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s gross unrealized gains?: Viridian Therapeutics, Inc. (VRDN) reported gross unrealized gains of $52K in Q1 2026.
How has Viridian Therapeutics, Inc.'s gross unrealized gains changed year-over-year?: Viridian Therapeutics, Inc.'s gross unrealized gains decreased by 90.1% year-over-year, from $523K to $52K.
What is the long-term trend for Viridian Therapeutics, Inc.'s gross unrealized gains?: Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s gross unrealized gains has grown at a 201.4% compound annual growth rate (CAGR), from $6K to $495K.